Next 10 |
2024-06-25 12:31:58 ET More on CSL CSL Seqirus to provide more than 40M bird flu vaccine doses to Europe Travere, CSL win conditional nod for kidney disease therapy in EU Seeking Alpha’s Quant Rating on CSL Historical earnings data for CSL Divi...
2024-06-14 10:59:33 ET More on bird flu CSL Seqirus to provide more than 40M bird flu vaccine doses to Europe Virax surges amid bird flu concerns Bird flu death in Mexico linked to strain not seen in humans before Third human bird flu case found...
2024-06-10 14:58:39 ET More on CSL, bird flu Bird flu death in Mexico linked to strain not seen in humans before Travere, CSL win conditional nod for kidney disease therapy in EU Seeking Alpha’s Quant Rating on CSL Historical earnings data for CSL ...
2024-06-05 16:48:37 ET More on GSK, Moderna, etc. GSK plc: Long-Term Cash Cow FDA advisors unanimously agree on COVID JN.1-lineage vaccine for fall COVID vaccine makers ready updated shots for fall immunization drive Moderna, Inc. (MRNA) Moderna Oncology Inve...
2024-05-30 13:46:56 ET More on CureVac, GSK, etc. GSK plc: Long-Term Cash Cow Pfizer: The Chart Looks Like A Bottom, But Is The Dividend Safe? Pfizer: Turning The Corner (Rating Upgrade) Moderna nearing deal to win U.S. funding for bird flu vaccine trial: FT ...
2024-05-30 07:04:27 ET More on Moderna Moderna: Betting On Bird Flu Rally Is A Poor Strategy For A Value Investor Aggressive Strides Forward For Moderna's Cancer Vaccine Moderna Q1: A Promising Pipeline Is Undervalued Moderna down ~9%, likely ending 10-sessio...
Phase 2 study to assess updated formulations for improved immune responses of multivalent vaccine candidate against influenza B strain Study initiated following previously reported interim data from Phase 2 Part of combined Phase 1/2 study in seasonal influenza Composition of vaccine ca...
2024-05-23 16:47:14 ET Summary CureVac N.V. is developing an avian influenza [H5N1] vaccine with GSK plc; A phase 1 study is already underway to evaluate this vaccine. It is working on a seasonal influenza vaccine, but further optimization is needed to target influenza B; Dose-opt...
Organizational redesign on track, trimming residual pandemic infrastructure and reducing 150 positions by year end U.S. FDA Fast Track designation granted for pre-pandemic avian influenza (H5N1) vaccine currently in Phase 1 development; candidate jointly developed with GSK Settlement wi...
2024-05-23 06:49:51 ET Summary Nvidia's Q1 results and guidance exceed expectations, leading to an increase in stock price and announcement of a 10-1 stock split. Live Nation Entertainment shares drop as the DOJ plans to announce an antitrust lawsuit against the company. Vacci...
News, Short Squeeze, Breakout and More Instantly...
Phase 2 study to assess updated formulations for improved immune responses of multivalent vaccine candidate against influenza B strain Study initiated following previously reported interim data from Phase 2 Part of combined Phase 1/2 study in seasonal influenza Composition of vaccine ca...
Organizational redesign on track, trimming residual pandemic infrastructure and reducing 150 positions by year end U.S. FDA Fast Track designation granted for pre-pandemic avian influenza (H5N1) vaccine currently in Phase 1 development; candidate jointly developed with GSK Settlement wi...
CureVac N.V. (NASDAQ: CVAC) is one of today's top gainers. The company's shares have moved 23.1% on the day to $4.05. CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing pr...